

個人履歷

基本資料

姓名 東雅惠 (Yaa-Hui Dong)

住址 臺北市北投區立農街二段 155 號 生物醫學大樓乙棟 214 室

電話 02-28267000 ext 7986

電子郵件 ydong3@nycu.edu.tw

研究專長

藥物流行病學

健康照護資料分析

系統回顧與統合分析

學歷

2008~2012	臺大流行病學與預防醫學研究所	博士
1999~2001	臺大藥學研究所醫院藥學組	碩士
1994~1998	臺大藥學系	學士

現職及工作經歷

2021~	陽明交通大學藥學系	副教授
2016~2021	陽明大學藥學系	助理教授
2014~2016	Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital and Harvard Medical School, US	Post-doctoral Research Fellow
2013~2014	國泰綜合醫院汐止分院藥劑科	諮詢藥師 (兼職)
2012~2013	臺灣大學健康資料研究中心	博士後研究員
2003~2008	國泰綜合醫院藥劑科	藥師
2003	中華景康藥學基金會	研究助理
2002~2003	和信治癌中心醫院藥劑科	藥師
2001~2002	臺大臨床藥學研究所	助教
1998~1999	馬偕紀念醫院藥劑科	藥師

專業學會

Membership of International Society for Pharmacoepidemiology (ISPE), Bethesda, MD, US

榮譽

2021~2023	陽明交通大學藥物科學院教師學術卓越獎勵
2019~2021	陽明大學藥物科學院教師學術卓越獎勵

- 2018~2019 陽明大學紀念沈力揚教授講師級研究與進修獎助
- 2016~2018 科技部補助大專校院延攬特殊優秀人才
- 2016 Best Reviewer of Pharmacoepidemiology and Drug Safety
- 2013 Scholarship of Postdoctoral Research Abroad Program, National Science Council, Taiwan
- 2013 Scholarship of International Conference on Pharmacoepidemiology & Therapeutic Risk Management
- 2012 Member of the Phi Tau Phi Scholastic Honor Society of the Republic of China
- 2006 Scholarship of Taiwan Fujisawa Foundation

著作目錄

(*corresponding author, #equal contribution)

期刊論文

1. **Dong YH**, Chang CH*, Lin JW*, Yang WS, Wu LC, Toh S (2022, May). Comparative cardiovascular effectiveness of glucagon-like peptide-1 receptor agonists versus sodium glucose cotransporter 2 inhibitors in patients with type 2 diabetes: a population-based cohort study. *Diabetes Obes Metab*. 2022 May 1. doi: 10.1111/dom.14741. Online ahead of print.
2. **Dong YH**, Chang CH*, Lin JW, Wu LC, Toh S (2022, May). Association between glucagon-like peptide-1 receptor agonists and biliary-related diseases in patients with type 2 diabetes: a nationwide cohort study. *Pharmacotherapy*. 2022 May 4. doi: 10.1002/phar.2688. Online ahead of print.
3. Wang H, Tsai YH, **Dong YH**, Liu JJ (2022, March). Young adult cancer incidence trends in Taiwan and the U.S. from 2002 to 2016. *Cancer Epidemiol*. 2022;78:102144.
4. Lin SY#, Chang YC#, Lin FJ, Tang SC, **Dong YH**, Wang CC (2022, March). Post-intracranial hemorrhage antithrombotic therapy in patients with atrial fibrillation. *J Am Heart Assoc*. 2022;11:e022849.
5. Sun SH, Chang CH, Zhan ZW, Chang WH, Chen YA, **Dong YH***. Risk of COPD exacerbations associated with statins versus fibrates: a new user, active comparison, and high-dimensional propensity score matched cohort study. *Int J Chron Obstruct Pulmon Dis*. 2021;16:2721-2733.
6. **Dong YH**, Wang JL, Lin JW* (2021, Jun). Fluoroquinolones and aortic disease-reply. *JAMA Intern Med*. 2021;181:881-882.
7. **Dong YH***, Chang CH*, Wang JL, Wu LC, Lin JW, Toh S (2020, Dec). Association of infections and use of fluoroquinolones with the risk of aortic aneurysm or aortic dissection. *JAMA Intern Med*. 2020;180:1587-1595.
8. Shin A, Park EH, **Dong YH**, Ha YJ, Lee YJ, Lee EB, Song YW, Kang EH* (2020, Nov). Comparative risk of osteoporotic fracture among patients with rheumatoid arthritis receiving TNF inhibitors versus other biologics: a cohort study. *Osteoporos Int*. 2020;31:2131-2139.
9. Chang TY, Chien JY, Wu CH, **Dong YH**, Lin FJ* (2020, May). Comparative safety and effectiveness of inhaled corticosteroid and long-acting β 2-agonist combinations in patients with COPD. *Chest*. 2020;157:1117-1129.
10. **Dong YH**, Wang SV, Gagne JJ, Wu LC, Chang CH* (2020, Feb). Comparison of

- different case-crossover variants in handling exposure-time trend or persistent-user bias: using dipeptidyl peptidase-4 inhibitors and the risk of heart failure as an example. *Value in Health*. 2020;23:217-226.
11. Zhan ZW, Chen YA, **Dong YH*** (2020, Feb). Comparative performance of comorbidity measures in predicting health outcomes in patients with chronic obstructive pulmonary disease. *Int J Chron Obstruct Pulmon Dis*. 2020;15:335-344.
 12. Lee YC, Wang JL*, **Dong YH**, Chen HC, Wu LC, Chang CH* (2019, Sep). Incidence of hospitalization for infection among patients with hepatitis B or C virus infection without cirrhosis in Taiwan: a cohort study. *PLoS Med*. 2019; 16:e1002894.
 13. Lin HD, Lai CL, **Dong YH**, Tu YK, Chan KA*, Suissa S (2019, Jun). Re-evaluating Safety and effectiveness of dabigatran versus warfarin in a nationwide data environment: a prevalent new-user design study. *Drugs- Real World Outcomes*. 2019;6:93-104.
 14. Wang JL#, **Dong YH#**, Ko WC*, Chang CH*, Wu LC, Chuang LM, Chen PC (2018, Dec). Thiazolidinediones and reduced risk of incident bacterial abscess in adults with type 2 diabetes: a population-based cohort study. *Diabetes Obes Metab*. 2018;20:2811-2820.
 15. Kumamaru H, Lee MP, Choudhry NK, **Dong YH**, Krumme AA, Khan N, Brill G, Kohsaka S, Miyata H, Schneeweiss S, Gagne JJ* (2018, Nov). Using previous medication adherence to predict future adherence. *J Manag Care Spec Pharm*. 2018;24:1146-55.
 16. **Dong YH**, Chang CH*, Wu LC, Hwang JS, Toh S (2018, May). Comparative cardiovascular safety of non-steroidal anti-inflammatory drugs in patients with hypertension: a population-based cohort study. *Br J Clin Pharmacol*. 2018;84:1045-1056.
 17. **Dong YH**, Jin Y, Tsacogianis TN, He M, Hsieh PH, Gagne JJ* (2018, Mar). Use of olmesartan and enteropathy outcomes: a multi-database study. *Aliment Pharmacol Ther*. 2018;47:792-800.
 18. **Dong YH**, Choudhry NK, Krumme A, Lee MP, Wu LC, Lai MS*, Gagne JJ (2017, Jun). Impact of hospitalization on medication adherence estimation in claims data. *J Clin Pharm Ther*. 2017;42:318-328.
 19. **Dong YH**, Bykov K, Choudhry NK, Donneyong MM, Huybrechts KF, Levin R, Schneeweiss S, Gagne JJ* (2017, Apr). Clinical outcomes of concomitant use of warfarin and selective serotonin reuptake inhibitors: a multidatabase observational cohort study. *J Clin Psychopharmacol*. 2017;37:200-209.
 20. **Dong YH**, Alcusky M, Maio V, Liu J, Liu M, Wu LC, Chang CH*, Lai MS,

- Gagne JJ (2017, Mar). Evidence of potential bias in a comparison of β blockers and calcium channel blockers in patients with chronic obstructive pulmonary disease and acute coronary syndrome: results of a multinational study. *BMJ Open*. 2017;7:e012997.
21. Bykov K, Schneeweiss S, Donneyong MM, **Dong YH**, Choudhry NK, Gagne JJ* (2017, Feb). Impact of an interaction between clopidogrel and selective serotonin reuptake inhibitors. *Am J Cardiol*. 2017;15;119:651-657.
 22. Lee YC, Chang CH*, **Dong YH**, Lin JW, Wu LC, Hwang JS, Chuang LM (2017, Feb). Comparing the risks of hospitalized heart failure associated with glinide, sulfonylurea, and acarbose use in type 2 diabetes: a nationwide study. *Int J Cardiol*. 2017;228:1007-1014.
 23. **Dong YH**, Chang CH*, Wu LC, Lai MS (2016, Oct). Use of cardioselective β -blockers and overall death and cardiovascular outcomes in patients with COPD: a population-based cohort study. *Eur J Clin Pharmacol*. 2016;72:1265-1273.
 24. Donneyong MM, Bykov K, Bosco-Levy P, **Dong YH**, Levin R, Gagne JJ* (2016, Sep). Risk of mortality with concomitant use of tamoxifen and selective serotonin reuptake inhibitors: multi-database cohort study. *BMJ*. 2016;354:i5014.
 25. Lo Y, Shen LJ, Chen WH, **Dong YH**, Wu FL* (2016, Sep). Risk factors of ifosfamide-related encephalopathy in adult patients with cancer: a retrospective analysis. *J Formos Med Assoc*. 2016;115:744-751.
 26. **Dong YH**, Chang CH*, Gagne JJ, Hsu CL, Lai MS (2016, Jan). Comparative cardiovascular and cerebrovascular safety of bronchodilators in patients with chronic obstructive pulmonary disease: a population-based cohort study. *Pharmacotherapy*. 2016;36:26-37.
 27. **Dong YH**#, Hsu CL#, Li YY, Chang CH*, Lai MS (2015, Sep). Bronchodilators use in patients with COPD . *Int J Chron Obstruct Pulmon Dis*. 2015;10:1769-1779.
 28. Weng TC#, Chang CH#, **Dong YH**, Chang YC, Chuang LM* (2015, Jul). Anemia and related nutrient deficiencies after Roux-en-Y gastric bypass surgery: a systematic review and meta-analysis . *BMJ Open* , 2015;5:e006964.
 29. **Dong YH**, Chang CH*, Mahler DA (2014, Dec). Response: secondary outcomes and Peto OR in meta-analysis . *Chest*. 2014;146:e212-e213.
 30. **Dong YH**, Lin JW, Wu LC, Chen CY, Chang CH*, Chen KY, Lai MS (2014, Dec). Examining the association between statins and lung cancer incidence in patients with type 2 diabetes mellitus. *J Formos Med Assoc*. 2014;113:940-948.
 31. Chen GL#, Hsiao FY#, **Dong YH**, Shen LJ*, Wu FL* (2014, Jul). Statins and the risk of liver injury: a population-based case-control study. *Pharmacoepidemiol Drug Saf*. 2014;23:719-725.

32. **Dong YH#**, Chang CH#, Wu FL, Shen LJ, Calverley PMA, Löfdahl CG, Lai MS*, Mahler DA (2014, Jun). Use of inhaled corticosteroids in patients with chronic obstructive pulmonary disease and the risk of tuberculosis and influenza: a systematic review and meta-analysis of randomized controlled trials. *Chest*. 2014;145:1286-1297.
33. **Dong YH**, Chang CH, Shau WY, Kuo RN, Lai MS*, Chan KA* (2013, Feb). Development and validation of a pharmacy-based comorbidity measure in a population-based automated healthcare database. *Pharmacotherapy*. 2013;33:126-136.
34. **Dong YH**, Lin HH, Shau WY, Wu YC, Chang CH*, Lai MS* (2013, Jan). Comparative safety of inhaled medications in patients with chronic obstructive pulmonary disease: systematic review and mixed treatment comparison meta-analysis of randomized controlled trials. *Thorax*. 2013;68:48-56.
35. Lascelles BD*, **Dong YH**, Marcellin-Little DJ, Thomson A, Wheeler S, Correa M (2012, Jan). Relationship of orthopedic examination, goniometric measurements, and radiographic signs of degenerative joint disease in cats. *BMC Vet Res*. 2012;8:10.
36. Kuo RN, **Dong YH**, Liu JP, Chang CH, Shau WY, Lai MS* (2011, Nov). Predicting healthcare utilization using a pharmacy-based metric with the WHO's Anatomic Therapeutic Chemical algorithm. *Med Care*. 2011;49:1031-1039.
37. **東雅惠***。氟喹諾酮(fluoroquinolones) 的主動脈傷害：怕萬一但又不能因噎廢食。結核醫訊 2021，44 期。頁 26-31。
38. 張意宜、江村煌、**東雅惠***。某區域醫院病人使用含碘顯影劑產生立即性不良反應之研究。臺灣臨床藥學雜誌 2013，21 卷 2 期。頁 1-10。
39. **東雅惠**、黃婉翠、林惜燕*。介紹日本醫院藥局藥事服務-以九州大學附設醫院藥劑部為例。藥學雜誌 2009，25 卷 3 期。頁 72-74。
40. **東雅惠**、林惜燕*。談日本病院藥劑管理指導-以九州大學附設病院藥劑部為例。藥學雜誌 2007，23 卷 4 期。頁 12-15。
41. **東雅惠**、黃婉翠、方信智、吳淑英、黃政華、徐志育、林惜燕*。某醫學中心門診病人上呼吸道感染抗生素使用之改善措施及其影響。臺灣家庭醫學研究 2007，5 卷 3 期。頁 97-107。